Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/13/2018 06/14/2018 06/15/2018 06/18/2018 06/19/2018 Date
102.86(c) 107.06(c) 107.8(c) 106.23(c) 104.62(c) Last
738 636 645 577 1 116 608 806 950 664 481 Volume
-2.88% +4.08% +0.69% -1.46% -1.52% Change
More quotes
Financials (USD)
Sales 2018 103 M
EBIT 2018 -701 M
Net income 2018 -700 M
Finance 2018 841 M
Yield 2018 -
Sales 2019 296 M
EBIT 2019 -607 M
Net income 2019 -616 M
Finance 2019 762 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 95,8x
EV / Sales2019 33,5x
Capitalization 10 678 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
01:03pALNYLAM PHARMACEUTICALS : Expands Senior Leadership Team with Two Key Appointmen..
BU
06/15ALNYLAM PHARMACEUTICALS : to Report New Clinical Results for Patisiran at the 4t..
BU
06/14ALNYLAM PHARMACEUTICALS : Receives Orphan Drug Designation from the United State..
AQ
06/14ALNYLAM PHARMACEUTICALS : Reports Updated Positive Results from Phase 1/2 Study ..
AQ
06/14ALNYLAM PHARMACEUTICALS : Over 700 Alnylam Employees volunteer at the Company's ..
AQ
06/13ALNYLAM PHARMACEUTICALS, INC. : Today's Research Reports on Trending Tickers: Al..
AC
06/12ALNYLAM PHARMACEUTICALS : Over 700 Alnylam Employees Volunteer at the Company&rs..
BU
06/12ALNYLAM PHARMACEUTICALS, INC. : Wired News – Alnylam Pharma Presented New Encour..
AC
06/12ALNYLAM PHARMACEUTICALS : `s Lumasiran yields positive results in phase 1/2 Hype..
AQ
06/08ALNYLAM PHARMACEUTICALS : Reports Updated Positive Results from Phase 1/2 Study ..
BU
More news
Sector news : Biotechnology & Medical Research - NEC
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
06/19Alnylam Pharmaceuticals $ALNY Downgraded to Buy at BidaskClub  
06/15Among our #bestoftheweek - Alnylam CEO: Six-digit price, value-based contrac.. 
06/14BidaskClub Downgrades Alnylam Pharmaceuticals $ALNY to Strong Sell  
06/13Get the latest news and updates for $ALNY $SMP $LPNT $NEXA $CAZA automaticall.. 
06/13Biotech industry group criticized for party featuring topless dancers  
More tweets
Qtime:64
News from SeekingAlpha
06/13Biotech industry group criticized for party featuring topless dancers 
06/12Nash players perk up on Galmed surge 
06/12Alnylam Pharmaceuticals Continues To Develop Options Outside Of Amyloidosis 
06/11YOUR DAILY PHARMA SCOOP : Zealand Dips, Eloxx Surges, Venetoclax Approved 
06/103 THINGS IN BIOTECH, JUNE 9 : AbbVie Rules The CLL Roost 
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Technical analysis trends ALNYLAM PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 148 $
Spread / Average Target 42%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Manmeet Singh Soni Chief Financial Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 678
CELLTRION, INC.--.--%33 912
IQVIA HOLDINGS INC7.13%21 394
LONZA GROUP3.38%20 435
INCYTE CORPORATION-21.91%15 677
SEATTLE GENETICS, INC.21.70%10 302